NCT06387342View on ClinicalTrials.gov

Namodenoson Treatment of Advanced Pancreatic Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 10, 2024

Primary Completion Date

July 15, 2026

Study Completion Date

December 15, 2026

Conditions
Pancreatic AdenocarcinomaPancreatic Cancer
Interventions
DRUG

Namodenoson 25mg

oral capsule

Trial Locations (1)

49100

RECRUITING

Rabin Medical Center Institute of Oncology, Petah Tikva

Sponsors

Lead Sponsor

Can-Fite BioPharma
All Listed Sponsors
lead

Can-Fite BioPharma

INDUSTRY